Elanco Animal Health Incorporated announced on July 2, 2025, an exclusive global license agreement with Neurizon Therapeutics Limited for Monepantel. Monepantel is the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans.
This agreement provides Neurizon with ongoing access to critical animal safety and manufacturing data, which is expected to significantly reduce near-term development costs and accelerate development timelines for NUZ-001. For Elanco, the deal involves a nominal upfront payment, small back-ended regulatory approval and commercial sale milestones, and single-digit royalty payments on future global net sales.
The partnership allows Elanco to leverage its scientific expertise to create broader value by contributing to human health innovation while focusing on its core animal health portfolio. Both companies are also working to finalize a supply agreement in the second half of 2025 to support Neurizon's clinical development and future commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.